申请人:Astellas Pharma Inc.
公开号:EP2394988A1
公开(公告)日:2011-12-14
An object of the present invention is to provide an excellent agent for treating or preventing dementia, schizophrenia based on serotonin 5-HT5A receptor modulating action.
It was discovered that acylguanidine derivatives, in which the guanidine is bonded to one ring of a naphthalene via a carbonyl group and a cyclic group is bonded to the other ring thereof, exhibit potent the 5-HT5A receptor modulating action and excellent pharmacological actions based on the action. The present invention is useful as an excellent agent for treating or preventing dementia, schizophrenia, bipolar disorder or attention deficit hyperactivity disorder.
本发明的目的是提供一种基于5-羟色胺5-HT5A受体调节作用的治疗或预防痴呆症、精神分裂症的优良药物。
研究发现,酰基胍衍生物(其中胍通过羰基键合在萘的一个环上,环基键合在其另一个环上)具有强效的 5-HT5A 受体调节作用和基于该作用的优异药理作用。本发明可作为治疗或预防痴呆症、精神分裂症、双相情感障碍或注意缺陷多动障碍的优良药物。